NYSE:VAPO - New York Stock Exchange, Inc. - US9221073052 - Common Stock - Currency: USD
NYSE:VAPO (12/14/2023, 8:19:45 PM)
1.27
+0.08 (+6.72%)
The current stock price of VAPO is 1.27 USD. In the past month the price decreased by -49.6%. In the past year, price decreased by -90.44%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
SYK | STRYKER CORP | 31.4 | 145.92B | ||
MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
DXCM | DEXCOM INC | 53.81 | 34.68B | ||
RMD | RESMED INC | 26.21 | 34.03B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Vapotherm Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Exeter, New Hampshire and currently employs 261 full-time employees. The company went IPO on 2018-11-14. Vapotherm, Inc. is a medical technology company. The company is focused on the care of patients of all ages suffering from the respiratory distress associated with lung diseases, such as chronic obstructive pulmonary disease, congestive heart failure, pneumonia, asthma and COVID-19. Its device solutions are focused on high velocity nasal insufflation (HVNI), which delivers non-invasive ventilatory support to patients suffering from respiratory distress. Its HVNI technology delivers heated, humidified and oxygenated air at a high velocity through a small-bore nasal interface. The company has five versions of its Precision Flow systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its High Velocity Therapy systems include a capital unit, a single-use disposable and a nasal interface. Its Precision Flow Hi-VNI system offers connectivity to a hospital’s nurse call system to alert the staff to disruption of the patient’s respiratory support.
VAPOTHERM INC
100 Domain Drive
Exeter NEW HAMPSHIRE 03833 US
CEO: Joseph Army
Employees: 261
Company Website: https://vapotherm.com/
Phone: 16036580411
The current stock price of VAPO is 1.27 USD. The price increased by 6.72% in the last trading session.
The exchange symbol of VAPOTHERM INC is VAPO and it is listed on the New York Stock Exchange, Inc. exchange.
VAPO stock is listed on the New York Stock Exchange, Inc. exchange.
8 analysts have analysed VAPO and the average price target is 1.02 USD. This implies a price decrease of -19.69% is expected in the next year compared to the current price of 1.27. Check the VAPOTHERM INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
VAPOTHERM INC (VAPO) has a market capitalization of 7.80M USD. This makes VAPO a Nano Cap stock.
VAPOTHERM INC (VAPO) currently has 261 employees.
The Revenue of VAPOTHERM INC (VAPO) is expected to grow by 5.53% in the next year. Check the estimates tab for more information on the VAPO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
VAPO does not pay a dividend.
VAPOTHERM INC (VAPO) will report earnings on 2024-02-21, after the market close.
VAPOTHERM INC (VAPO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-14.54).
ChartMill assigns a fundamental rating of 2 / 10 to VAPO. Both the profitability and financial health of VAPO have multiple concerns.
Over the last trailing twelve months VAPO reported a non-GAAP Earnings per Share(EPS) of -14.54. The EPS increased by 34.56% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -86.17% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 45% to VAPO. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 81.61% and a revenue growth 5.53% for VAPO